Adherence to daily pills is a major challenge for HIV prevention. Dr. Sehulong Robert Moraba was at the forefront of a potential paradigm shift, serving as Principal Investigator for the groundbreaking Phase 3 GS-US-528-9023 trial. This study evaluated the efficacy and safety of subcutaneous, twice-yearly long-acting Lenacapavir for PrEP.
Focused on cisgender men, transgender individuals, and gender non-binary people who have sex with men (SAHPRA ref: 20210504), this trial represented the longest-acting PrEP modality ever studied. Dr. Moraba’s leadership was instrumental in testing this revolutionary “six-month shot,” which could dramatically reduce the adherence burden and increase the impact of HIV prevention programs.
